fyonibio产品代理
fyonibio产品代理
我们的 QMS 基于 ISO 9001:2015 和良好临床实验室规范 (1,2) 的要求。此外，我们整合了 GCP、GMP 和 GLP 指南的基石，不仅要追求卓越和持续改进的质量，还要坚持患者安全和数据完整性的原则。
此外，QMS 旨在满足 FyoniBio 自己的要求、行业最佳实践和客户特定要求。
质量始于和止于客户，我们的目标是始终满足他们的需求。这反映在我们的灵活性和我们在协助每个客户进行特定药物开发工作时的实践方法。
我们的客户将与各自领域的专家进行交流和合作，建立富有成效且相互信任的关系，以实现共同目标。
我们履行职责，保护员工的健康和利益、业务合作伙伴的利益以及环境。
GCP 检查员工作组于 2012 年 2 月 28 日通过了对进行临床试验样品分析或评估的实验室的反思文件 (EMA/INS/GCP/532137/2010)
世界卫生组织 (WHO) 的良好临床实验室规范，代表热带病研究和培训特别规划，2009 年。
We all at FyoniBio are dedicated to deliver high quality services tailored to each of our customer.
Our QMS is based on the requirements of ISO 9001:2015 and Good Clinical Laboratory Practices (1,2). Additionally, we have integrated the corner stones of GCP, GMP and GLP guidelines to strive not only for excellent and continuously improved quality but also for upholding the principles of patient safety and data integrity.
Furthermore, the QMS is designed to enable the fulfilment of FyoniBio’s own requirements, industry best practices and customer specific requirements.
Quality begins and ends with the customer and we aim to always satisfy their needs. This is reflected in our flexibility and in our hands-on approach in accompanying each individual customer in their specific drug development endeavour.
Our customers will be communicating and working with experts in their fields in a fruitful and trusting relationship to achieve common goals.
We meet our responsibilities to protect the health and interests of our employees, the interests of our business partners as well as the environment.
Reflection paper for laboratories that perform the analysis or
evaluation of clinical trial samples (EMA/INS/GCP/532137/2010) adopted by GCP Inspectors Working Group on 28 February 2012
Good Clinical Laboratory Practice of the World Health Organization (WHO) on behalf of the Special Programme for Research and Training in Tropical Diseases, 2009.
